29.65
1.89%
-0.57
Pre-market:
29.90
0.25
+0.84%
Genmab ADR stock is currently priced at $29.65, with a 24-hour trading volume of 587.48K.
It has seen a -1.89% decreased in the last 24 hours and a +0.75% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $30.12 pivot point. If it approaches the $29.44 support level, significant changes may occur.
Previous Close:
$30.22
Open:
$29.71
24h Volume:
587.48K
Market Cap:
$19.15B
Revenue:
$2.58B
Net Income/Loss:
$794.60M
P/E Ratio:
29.58
EPS:
1.0022
Net Cash Flow:
$781.65M
1W Performance:
+2.92%
1M Performance:
+0.75%
6M Performance:
-7.23%
1Y Performance:
-28.64%
Genmab ADR Stock (GMAB) Company Profile
Name
Genmab ADR
Sector
Industry
Phone
45 70 20 27 28
Address
Kalvebod Brygge 43, Copenhagen
Genmab ADR Stock (GMAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
Dec-06-23 | Upgrade | UBS | Neutral → Buy |
Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-24-23 | Initiated | BTIG Research | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
May-31-23 | Initiated | UBS | Neutral |
May-12-23 | Initiated | Morgan Stanley | Underweight |
Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
Nov-14-22 | Initiated | William Blair | Mkt Perform |
Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
May-02-22 | Initiated | Cowen | Market Perform |
Mar-16-22 | Upgrade | UBS | Neutral → Buy |
Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
Dec-01-21 | Initiated | Berenberg | Sell |
Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-20-21 | Initiated | Deutsche Bank | Buy |
Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
Apr-23-20 | Initiated | Credit Suisse | Outperform |
Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
Jan-13-20 | Initiated | SunTrust | Buy |
Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-12-19 | Initiated | Guggenheim | Buy |
Aug-12-19 | Initiated | Morgan Stanley | Overweight |
Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab ADR Stock (GMAB) Latest News
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag - Yahoo Singapore News
Yahoo Singapore News
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now? - Yahoo Singapore News
Yahoo Singapore News
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Singapore News
Yahoo Singapore News
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Singapore News
Yahoo Singapore News
Decoding 9 Analyst Evaluations For Genmab
Benzinga
Genmab ADR Stock (GMAB) Financials Data
Genmab ADR (GMAB) Revenue 2024
GMAB reported a revenue (TTM) of $2.58 billion for the quarter ending March 31, 2024, a +21.88% rise year-over-year.
Genmab ADR (GMAB) Net Income 2024
GMAB net income (TTM) was $794.60 million for the quarter ending March 31, 2024, a +10.17% increase year-over-year.
Genmab ADR (GMAB) Cash Flow 2024
GMAB recorded a free cash flow (TTM) of $781.65 million for the quarter ending March 31, 2024, a -11.30% decrease year-over-year.
Genmab ADR (GMAB) Earnings per Share 2024
GMAB earnings per share (TTM) was $1.2067 for the quarter ending March 31, 2024, a +10.37% growth year-over-year.
About Genmab ADR
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Cap:
|
Volume (24h):